Sangamo Therapeutics, Inc.
SGMO
$0.5863
$0.01312.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 184.39% | -14.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 184.39% | -14.75% | |||
| Cost of Revenue | 9.18% | 4.78% | |||
| Gross Profit | 52.21% | -13.92% | |||
| SG&A Expenses | -9.76% | 3.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.72% | 4.26% | |||
| Operating Income | 37.19% | -9.80% | |||
| Income Before Tax | 34.51% | -27.94% | |||
| Income Tax Expenses | -77.31% | 127.87% | |||
| Earnings from Continuing Operations | 34.68% | -30.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 34.68% | -30.78% | |||
| EBIT | 37.19% | -9.80% | |||
| EBITDA | 38.48% | -11.19% | |||
| EPS Basic | 43.99% | -24.80% | |||
| Normalized Basic EPS | 41.64% | -14.94% | |||
| EPS Diluted | 43.99% | -19.84% | |||
| Normalized Diluted EPS | 41.64% | -14.94% | |||
| Average Basic Shares Outstanding | 16.65% | 4.80% | |||
| Average Diluted Shares Outstanding | 16.65% | 4.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||